How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,073 results for

Antithyroid Drug

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Genetic variants associated with antithyroid drug-induced agranulocytosis

Genetic variants associated with antithyroid drug-induced agranulocytosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect (...) articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text

2018 PROSPERO

42. Antithyroid Drug

with Methimazole Hepatitis Occurs with both Methimazole and Propylthiouracil (PTU) Methimazole associated hepatitis : 3.17 per 1000 person-years : 0.32 per 1000 person-years Propylthiouracil (PTU) is associated with severe liver injury Adults: 1 in 10,000 Children: 1 in 2,000 -like syndrome Rash or Switch from PTU to Methimazole if severe or Congenital abnormalities possible with Methimazole VI. Monitoring Repeat examination every 3 months before starting therapy Lab Testing while on antithyroid medications (...) SnomedCT 5067008 , 418416001 English Antagonists, Thyroid , Antithyroid Drugs , Drugs, Antithyroid , Thyroid Antagonists , thyroid inhibitor , Agents, Antithyroid , Antithyroid Agents , THYROID ANTAG , ANTITHYROID AGENTS , anti-thyroid agents , anti-thyroid agents (medication) , thyroid antagonists , [HS852] ANTITHYROID AGENTS , antithyroid drug , inhibitors thyroid , antithyroid agents , antithyroid preparations , antithyroid drugs , Thyroid Antagonist , ANTITHYROID PREPARATIONS , Thyroid antagonists

2018 FP Notebook

43. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study (Full text)

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study Immune checkpoint inhibitors, including anti-programmed cell death-1 (PD-1) antibodies, have become promising treatments for a variety of advanced malignancies. However, these medicines can cause immune-related adverse events (irAEs), including endocrinopathies.This study examined the incidence of endocrine irAEs induced by nivolumab.Sixty-six patients treated with nivolumab (...) at Nagoya University Hospital were prospectively evaluated for pituitary hormones, thyroid function, antithyroid antibodies (Abs), and glucose levels every 6 weeks after the initiation of nivolumab for 24 weeks.Four out of 66 patients developed destructive thyroiditis, and three patients developed hypothyroidism requiring levothyroxine replacement. The prevalence of positive anti-thyroglobulin Abs (TgAbs) and/or anti-thyroid peroxidase Abs (TPOAbs) at baseline was significantly higher in the group

2018 Journal of the Endocrine Society PubMed abstract

44. Antithyroid Drug Side Effects in the Population and in Pregnancy. (Full text)

Antithyroid Drug Side Effects in the Population and in Pregnancy. Methimazole (MMI) and propylthiouracil (PTU) are both associated with birth defects and may also rarely be associated with agranulocytosis and liver failure. The frequency of these side effects when antithyroid drugs (ATDs) are used in the population in general or in pregnancy remains to be elucidated.All individuals registered as the parent of a live-born child in Denmark, 1973–2008, were identified (n = 2 299 952) and studied

2016 Journal of Clinical Endocrinology and Metabolism PubMed abstract

45. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: A retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. (Abstract)

Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: A retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Antithyroid drug (ATD)-induced agranulocytosis is a rare but life-threatening disease. Clinical features of ATD-induced agranulocytosis and outcomes remain incompletely understood.Patients with clinically diagnosed ATD-induced agranulocytosis were (...) retrospectively studied, involving 9690 patients who were referred for radioiodine treatment during a 15-year period (2000-2015) in China. There were 114 cases of agranulocytosis attributable to ATD included, and their clinical characteristics and therapy outcomes were analyzed.The female-to-male ratio of ATD-induced agranulocytosis was 10.4:1. The mean age (±standard deviation) of the patients with ATD-induced agranulocytosis was 41.7 ± 12.3 years. The methimazole and propylthiouracil doses given

2016 Thyroid

46. Antithyroid drug-associated MPO-ANCA-positive tubulointerstitial nephritis in a type 2 diabetes patient: a case report (Full text)

Antithyroid drug-associated MPO-ANCA-positive tubulointerstitial nephritis in a type 2 diabetes patient: a case report A 54-year-old man diagnosed with type 2 diabetes and hyperthyroidism was prescribed propylthiouracil (PTU) after the patient developed hepatic dysfunction on thiamazole. At 50 mg/day of PTU, he was stable with thyroid-stimulating hormone receptor and thyrotropic antibody titers remaining stable. After four years of taking PTU, he was referred to the Department of Nephrology due

2016 CEN Case Reports PubMed abstract

47. The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation (Full text)

The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation Antithyroid drugs (ATDs) have been shown to attenuate the effectiveness of radioiodine (radioiodine ablation, RIA) therapy in Graves' disease. We undertook a study to look at the impact of iodine uptakes on the outcome of (131)I therapy. To determine the effect of prior ATD use on the duration of time to achieve cure in patients with high vs intermediate uptake Graves (...) of low free thyroxin and rising TSH levels. When a standard dose of 15 mCi (131)I was administered, a cure rate of 93% was achieved. The median duration of time to cure (TC) was 129 days. Surprisingly, a direct proportional linear relationship (R(2)=0.92) was established between time to cure and radioiodine uptake (TC> 3 0%=172days, TC10 - 3 0%=105 days, P<0.001). Patients who used ATD medications took a proportionately longer duration to achieve remission (TCNO ATD=102days, TCATD=253days, P<0.001

2016 Endocrine connections PubMed abstract

48. Antithyroid drug induced agranulocytosis: what still we need to learn ? (Full text)

Antithyroid drug induced agranulocytosis: what still we need to learn ? Antithyroid drugs (ATDs) induced agranulocytosis is a rare but life threatening condition. We report a 29 years Filipino female diagnosed as having hyperthyroidism with normal base line blood counts, liver and renal profile. She was started on maximum 60 mg (20mg TID) oral dose of carbimazole since one month by her treating physician. Exactly after one month of treatment she presented to emergency room (ER) with fever, sore

2016 The Pan African medical journal PubMed abstract

49. Predicting relapse of Graves' disease following treatment with antithyroid drugs (Full text)

and 12 months post-treatment. Patients with GD exhibiting large thyroids, high pre-mediation TRAb levels and elevated FT3/FT4 ratios responded less markedly to antithyroid drug treatments, as compared with patients not exhibiting these prognostic factors. Furthermore, patients with large thyroids, post-medication ophthalmopathy and continued thyrotropin suppression demonstrated higher rates of recurrence. (...) Predicting relapse of Graves' disease following treatment with antithyroid drugs The aim of the present study was to monitor long term antithyroid drug treatments and to identify prognostic factors for Graves' disease (GD). A total of 306 patients with GD who were referred to the Endocrinology Clinic at Weifang People's Hospital (Weifang, China) between August 2005 and June 2009 and treated with methimazole were included in the present study. Following treatment, patients were divided into non

2016 Experimental and therapeutic medicine PubMed abstract

50. Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease (Full text)

Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease Hyperthyroidism relapse in Graves disease after antithyroid drug (ATD) withdrawal is common; however, measuring the thyrotropin receptor antibody (TRAb) at ATD withdrawal in order to predict outcomes is controversial. This study compared measurement of thyroid stimulatory antibody (TSAb) and thyrotropin-binding inhibitory immunoglobulin (TBII) at ATD (...) withdrawal to predict relapse.This retrospective study enrolled patients with Graves disease who were treated with ATDs and whose serum thyroid-stimulating hormone levels were normal after receiving low-dose ATDs. ATD therapy was stopped irrespective of TRAb positivity after an additional 6 months of receiving the minimum dose of ATD therapy. Patients were followed using thyroid function tests and TSAb (TSAb group; n=35) or TBII (TBII group; n=39) every 3 to 6 months for 2 years after ATD

2016 Endocrinology and Metabolism PubMed abstract

51. Periodic Granulocyte Count Measuring Is Useful for Detecting Asymptomatic Agranulocytosis in Antithyroid Drug-Treated Patients with Graves' Disease (Full text)

Periodic Granulocyte Count Measuring Is Useful for Detecting Asymptomatic Agranulocytosis in Antithyroid Drug-Treated Patients with Graves' Disease Finding agranulocytosis (AG) at an early stage is important to improve outcome, but periodic granulocyte count monitoring is not generally recommended for patients with Graves' disease, because AG develops suddenly.At the Kuma Hospital, Graves' patients under antithyroid drug (ATD) treatment in an outpatient clinic have a granulocyte count (...) at an outpatient clinic. The remaining 9 patients visited the Kuma Hospital or other hospitals because of infection symptoms. Most of the AG patients were given granulocyte colony-stimulating factor injections immediately and were admitted if a prompt increase in granulocytes could not be obtained. The final treatments for Graves' disease were 131I-radioisotope therapy (19 patients), thyroidectomy (2 patients), inorganic iodine (1 patient), or another ATD (1 patient). Among the 33 GP patients, 31 (94

2016 European thyroid journal PubMed abstract

52. Erratum: antithyroid drug induced agranulocytosis: what still we need to learn? (Full text)

Erratum: antithyroid drug induced agranulocytosis: what still we need to learn? [This corrects the article DOI: 10.11604/pamj.2016.23.27.8365.].

2016 The Pan African medical journal PubMed abstract

53. Dual binding mode of antithyroid drug methimazole to mammalian heme peroxidases – structural determination of the lactoperoxidase–methimazole complex at 1.97 Å resolution (Full text)

Dual binding mode of antithyroid drug methimazole to mammalian heme peroxidases – structural determination of the lactoperoxidase–methimazole complex at 1.97 Å resolution Lactoperoxidase (LPO, EC 1.11.1.7) is a member of the mammalian heme peroxidase family which also includes thyroid peroxidase (TPO). These two enzymes have a sequence homology of 76%. The structure of LPO is known but not that of TPO. In order to determine the mode of binding of antithyroid drugs to thyroid peroxidase, we (...) have determined the crystal structure of LPO complexed with an antithyroid drug, methimazole (MMZ) at 1.97 Šresolution. LPO was isolated from caprine colostrum, purified to homogeneity and crystallized with 20% poly(ethylene glycol)-3350. Crystals of LPO were soaked in a reservoir solution containing MMZ. The structure determination showed the presence of two crystallographically independent molecules in the asymmetric unit. Both molecules contained one molecule of MMZ, but with different

2016 FEBS open bio PubMed abstract

54. The second antithyroid drug treatment is effective in relapsed Graves' patients: a median 11-year follow-up study. (Abstract)

The second antithyroid drug treatment is effective in relapsed Graves' patients: a median 11-year follow-up study. Antithyroid drug (ATD) is a widely used treatment for Graves' disease (GD). However, its long-term efficiency remains unclear. This study investigated the long-term disease prognosis and predictive factors for relapse in ATD-treated GD patients.Newly diagnosed, ATD-treated GD patients with at least four years of follow-up were recruited (n = 187). Remission was defined

2016 Thyroid

55. Cost-Utility Analysis Comparing Radioactive Iodine, Antithyroid Drugs and Total Thyroidectomy for Primary Treatment of Graves' Disease. (Full text)

Cost-Utility Analysis Comparing Radioactive Iodine, Antithyroid Drugs and Total Thyroidectomy for Primary Treatment of Graves' Disease. Little data is in existence about the most cost-effective primary treatment for Graves' disease. We performed a cost-utility analysis comparing radioactive iodine (RAI), anti-thyroid drugs (ATD) and total thyroidectomy (TT) as first-line therapy for Graves' disease in England and Australia.We used a Markov model to compare lifetime costs and benefits (quality (...) -adjusted life-years (QALYs)). The model included efficacy, rates of relapse and major complications associated with each treatment, and alternative second-line therapies. Model parameters were obtained from published literature. One-way sensitivity analyses were conducted. Costs were presented in 2015£ or Australian Dollars (AUD).RAI was the least expensive therapy in both England (£5425; QALYs 34.73) and Australia (AUD5601; 30.97 QALYs). In base case results, in both countries, ATD was a cost

2016 European Journal of Endocrinology PubMed abstract

56. Characteristics of Korean Patients with Antithyroid Drug-Induced Agranulocytosis: A Multicenter Study in Korea (Full text)

Characteristics of Korean Patients with Antithyroid Drug-Induced Agranulocytosis: A Multicenter Study in Korea Antithyroid drugs (ATDs) can lead to the development of agranulocytosis, which is the most serious adverse effect. Characteristics of ATD-induced agranulocytosis (AIA) have seldom been reported due to the rarity. In this study, we characterized the clinical features for AIA in Korean patients.We retrospectively reviewed data from patients with AIA diagnosed between 1997 and 2014

2015 Endocrinology and Metabolism PubMed abstract

57. Better adherence to antithyroid drug is associated with decreased risk of stroke in hyperthyroidism patients. (Abstract)

Health Insurance Research database. Each patient was individually tracked for 5 years from their index date (beginning the antithyroid drugs) to identify those who suffered from new episode of ischaemic stroke. Medication possession ratio (MPR) was used to represent the antithyroid drug compliance. The association between the MPR and the risk of stroke was examined.The stroke incidence rates for hyperthyroidism patients with age < 45 years and age ≥ 45 years were 0.42 and 3.76 per 1000 person-years (...) Better adherence to antithyroid drug is associated with decreased risk of stroke in hyperthyroidism patients. An increased risk for ischaemic stroke has been reported in young hyperthyroidism patients independent of atrial fibrillation (AF). However, whether the use of antithyroid drugs in hyperthyroidism patients can reduce the occurrence of ischaemic stroke remains unclear.A total of 36,510 newly diagnosed hyperthyroidism patients during 2003-2006 were identified from the Taiwan National

2015 International journal of clinical practice

58. Mode of binding of the antithyroid drug propylthiouracil to mammalian haem peroxidases. Erratum (Full text)

Mode of binding of the antithyroid drug propylthiouracil to mammalian haem peroxidases. Erratum The results in the article by Singh et al. [(2015), Acta Cryst. F71, 304-310] have been brought into question and the article is retracted.

2015 Acta crystallographica. Section F, Structural biology communications PubMed abstract

59. Congenital Anomalies in Children Exposed to Antithyroid Drugs In-Utero: A Meta-Analysis of Cohort Studies. (Full text)

Congenital Anomalies in Children Exposed to Antithyroid Drugs In-Utero: A Meta-Analysis of Cohort Studies. Hyperthyroidism affects about 0.2%-2.7% of all pregnancies, and is commonly managed with antithyroid drugs (ATDs). However, previous studies about the effects of ATDs on congenital anomalies are controversial. Therefore, the present meta-analysis was performed to explore the risk of congenital anomalies in children exposed to ATDs in-utero.Embase, Pubmed, Web of Knowledge, and BIOSIS

2015 PloS one PubMed abstract

60. Thyroidectomy Versus Medical Management for Euthyroid Patients With Hashimoto Disease and Persisting Symptoms: A Randomized Trial. (Abstract)

medical therapy.Randomized trial. (ClinicalTrials.gov: NCT02319538).Secondary care hospital in Norway.150 patients aged 18 to 79 years with persistent Hashimoto-related symptoms despite euthyroid status while receiving hormone replacement therapy and with serum antithyroid peroxidase (anti-TPO) antibody titers greater than 1000 IU/mL.Total thyroidectomy or medical management with hormone substitution to secure euthyroid status in both groups.The primary outcome was general health score on the Short (...) disease, and follow-up was limited to 18 months.Total thyroidectomy improved health-related quality of life and fatigue, whereas medical therapy did not. This improvement, along with concomitant elimination of serum anti-TPO antibodies, may elucidate disease mechanisms.Telemark Hospital.

2019 Annals of Internal Medicine Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>